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ABSTRACT
Pseudomyxoma peritonei is a devastating gastrointestinal disease characterized by
the production of mucinous ascites within the peritoneal cavity. Historically, this
condition is discovered in the advanced state due to the lack of adequate screening tests
and typically presents as an enlarged abdomen and with symptoms of gastrointestinal
distress. Treatment for this disease is a combination of cytoreductive surgery and heated
intraperitoneal perfusion chemotherapy, but a successful operation does not guarantee
full remission of this malignancy. This study focuses on 3 untested variants of PMP
cancer, and 2 mucinous colorectal adenocarcinomas that had invaded into the peritoneal
cavity. Clinical presentation of the mucinous colorectal adenocarcinomas with peritoneal
invasion resembles PMP cancer. Tumor biopsies were obtained through Mercy Medical
Center in Baltimore, Maryland. These cancers underwent 2 growth experiments to obtain
both the doubling rate and to explore ex vivo whether or not each unique proliferative
rate impacted chemotherapy agent sensitivities. Four common colorectal cancer
chemotherapies were examined and their interactions analyzed alongside 5 cancers.
LD50 was calculated for each unique interaction between the chemotherapy agent and the
cancers, and this LD50 was compared to clinically relevant plasma concentrations for the
agent established through literature searches. The results dictate that Mitomycin C and 5Fluorouracil were the most effective solitary chemotherapy agents. Oxaliplatin therapy
showed some sensitivity, but the required concentration to achieve a 50% reduction in
ATP values lay beyond normal plasma concentration parameters. Irinotecan therapy
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yielded little sensitivity, showing that Irinotecan was unable to inhibit normal cellular
growth even at peak tested concentrations. We decided to modestly explore multi-drug
interactions after the disappointing Irinotecan results, combining 5-Fluorouracil and
Irinotecan to create a more robust Irinotecan data pool. Results from the combination
therapy were more promising, with each cancer showing sensitivity to the treatment.
However, calculated LD50 for the Irinotecan concentrations in the multidrug therapy
were in excess of clinical accepted plasma concentrations. Multi-drug therapy shows
promise in the treatment of these specific cancers, and future experimentation should
expand to include other common combination therapies.
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CHAPTER 1
INTRODUCTION
1.1 What is Pseudomyxoma Peritonei
Pseudomyxoma peritonei (PMP) is a rare gastrointestinal disease affecting
patients across sexual, geographical, and racial boundaries. Historical data shows that
females are more likely to develop PMP than males (60:40), and the development of
PMP occurs later in life 9. The accepted clinical definition of PMP has evolved since the
discovery of the disease over a century ago. The latest data describes PMP as a condition
arising from appendiceal neoplasms. There has been evidence of origination from the
colon and other regional gastrointestinal organs, but this is a rarity rather than the
accepted norm and further classified as invasive colorectal cancer 45. The clinical sign of
PMP has been the increase in abdominal size in patients, deriving from the endless
production of mucin inside the peritoneal cavity. This mucin originates, typically, from
an appendicular tumor that has ruptured. Epithelial cells are able to escape from the
ruptured neoplasm, and into the peritoneal cavity. Once in the peritoneal cavity these
epithelial cells are free to proliferate and produce mucus. It is shown that the cells,
suspended in mucus, typically do not bind to surfaces within the cavity due to the lack of
adhesion molecules expressed on the cells. This allows the mucus to move seamlessly
along the organs as a result of peristalsis and follow gravity’s pull to the bottom of the
peritoneal cavity 44, 55. Visibly, the patient will present the macro effect of this
redistribution with the aforementioned increase in their abdominal area. CT scans are the
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most appropriate imaging for the diagnosis of PMP, however the mucinous material itself
is difficult to see 30, 3. Predominantly, early detection of PMP is notoriously difficult due
to the lack of dense material inside the peritoneal cavity. Once the disease progresses to a
more advanced stage, calcification of material is more readily seen and follows the innate
peritoneal fluid motion 58. However, as the condition advances the specificity of CT is
lost and the organs within the cavity are compartmentalized due to the disruptive nature
of the growing omental cake 58. MRI, PET, and PET CT is shown to be less effective as
imaging techniques for the detection and progression of PMP. These techniques could be
beneficial in the identification of possible metastasis 3, 54. True confirmation of a PMP
diagnosis is performed with laparoscopy and subsequent biopsies 3, 57.
1.2 Common Mutations Present in PMP
PMP cancers are known to have numerous mutations which pathologically can
determine the degree of aggression of the disease. PMP is divided into two types:
disseminated peritoneal adenomucinosis (DPAM) or peritoneal mucinous
adenocarcinomas (PMCA). DPAM is considered the less aggressive type of PMP.
PMCA, however, is shown to invade organ tissue causing significant damage and have
high levels of epithelial proliferation. KRAS gene mutations are common, while GNAS
gene mutations are rarer 47, 43. Often, a combination of KRAS and GNAS mutations are
found within PMP cancers. Noguchi found evidence of TP53 mutations within PMCA
patient samples, but none within DPAM samples. It was theorized that the TP53 mutation
promotes the aggressive malignant nature of PMCA 47. TP53 is a common mutation in
cancer and is responsible for Li-Fraumeni syndrome. P53 activates the expression of p21
after recognition of nuclear damage 14, 35. It was also shown in a study performed by
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Guidos et all that p53 - scid deficient mice are unable to stop cell cycle progression with
double strand breaks in DNA. With the checkpoint rendered ineffective, the mice
developed disseminated pro-b or immature T cell lymphoma 21.
KRAS is an oncogene, and studies have shown that KRAS mutations are apparent
in up to 45% of colorectal cancers. KRAS is responsible for the p21 protein, a GTPase
responsible for EGFR-signaling intracellularly 61, 32. When mutated, KRAS GTPase
activity is inhibited and p21 is locked in the GTP bound form. When locked into this
active form, cell growth is accelerated by activated proliferative pathways 61, 4, 50.
It is common to detect mutations in the GNAS gene with mucinous neoplasms of
the appendix, colon, and pancreas 17. It is then not surprising that PMP, which is known
to typically originate from mucinous neoplasms of the appendix, would in turn also have
a propensity for GNAS gene mutations. The GNAS gene encodes for a guanine
nucleotide-binding protein α (Gsα) subunit. This protein receives signals from G-protein
coupled receptors and passes this signal to adenyl cyclase which in turn influences the
expression of cyclic adenosine monophosphate 36. There are two significant mutation
variants seen in PMP patients both located on chromosome 20. A single nucleotide
mutation of thymine to adenine causes a shift from the wild type arginine amino acid to
cysteine and histidine. This leads to a decrease in GTPase activity due to the mutated
structure. The mutated protein is unable to effectively hydrolyze GTP, thereby staying
within the active status and stimulating subsequent pathways 36. The Nishikawa study
validated the relationship between GNAS mutations and mucin production
experimentally in CRC by measuring elevated levels of cAMP, MUC2, and MUC5AC 46,
36

. Elevated cAMP levels are theorized to stimulate both the cAMP response element
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bind protein and activating transcription factor, which binds to mucin genes to increase
mucin expression 62, 36.
1.3 Cancer Growth
Cellular growth is ubiquitous nearly everywhere within the human body.
Proliferation of cells ensure a timely and productive turnover of older cells to that of
newer and healthier cells. However, cellular growth is checked by two synergistic
features of multicellular organisms, contact inhibition of proliferation and contact
inhibition of motility. Typical human cells do not proliferate endlessly after reaching an
appropriate cellular density, with some exceptions of certain normal physiological
variables 48,41. Cell to cell contact activates numerous signaling pathways including Ecadherin proteins 42. Studies have shown that cancerous cell lines fail to express Ecadherin at detectable levels, where as normal healthy cells have abundant E-cadherin
proteins at lesser cellular densities 53. Cancer metastasis hinges upon E-cadherin absence
in cells. The lack of this critical membrane protein allows for cells to invade surrounding
tissue, thereby bypassing contact inhibition of locomotion 42. Due to the extreme
proliferation rate of cancerous tumors, chemotherapeutic agents have been devised to
capitalize and preferentially attack cells that divide at a higher rate than surrounding
tissue. The high division rate, and the hypoxic conditions of solid-state tumors, leaves
them open to therapeutic intervention.
1.4 Treatment of PMP Cancer Historically
Despite the heroic efforts of countless surgeons and physicians a diagnosis of
PMP does not always have positive outcomes. While PMP shares many similarities with
other malignant cancers, it has been shown historically that PMP requires a multi-
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targeted approach. The treatment draws inspiration from numerous sources, and can be
best described as a combination of aggressive cytoreductive surgery (CRS) and Heated
intraperitoneal perfusion chemotherapy (HIPEC). Studies have shown that in patients
suffering with PMP, CRS without HIPEC is far less effective than the combination. CRS
will reduce all visible signs of malignancy; however, the procedure could also allow
some malignant cells to burrow deeper within the patient’s abdomen or pelvis if not all
cancer cells are removed. In addition, malignant cells that have already invaded into the
tissue would not be removed by CRS alone 56. This in turn could lead to additional
negative physiological effects for the patient’s gastrointestinal or renal system as a result
of the spreading cancer. Administration of HIPEC after CRS has been shown to reduce
this possibility 56. CRS is utilized in the treatment plans for both benign and malignant
non-PMP tumors. The intention is to remove all visual evidence of the PMP derived
mucin and epithelial cells within the patient’s abdominal cavity. After successful CRS,
the patient is administered HIPEC while in the surgical theatre. Chemotherapeutic drugs
are heated to 41°C and are introduced into the patient’s peritoneal cavity. It is shown that
hyperthermic temperatures increase the efficacy of therapeutical agents, and in cases of
more traditional CRC reduce the rate of tumor reoccurrence 56, 25. Similar studies have
shown that hyperthermic conditions alone will negatively impact the proliferation of
CRC cells 25. The heated drug bathes the internal cavity of the patient, and is
subsequently removed by suction. This therapy is more effective than traditional systemic
chemotherapy due to the lack of vascularization within the cavity itself 44. HIPEC without
CRS is shown to be less effective than the combination of both procedures.
Chemotherapeutics, when given in this manner, rely on passive diffusion to reach
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malignant cells and studies have shown that this penetration ranges from the surface cells
to possibly 3mm 38. Administration of chemotherapy drugs in this manner allows for
maximum coverage of the affected areas within the peritoneal cavity. The concentration
of drugs used in HIPEC are typically higher than that of traditional systemic
chemotherapy with the same drugs. Due to the lack of vascularization within the
peritoneal cavity, there is low risk of the full therapeutic dose invading systemic
circulation 64. This anatomical feature provides a distinct advantage to HIPEC, but also
restricts the effectiveness of traditional systemic chemotherapy. Without a direct flow of
arterial blood, it would be otherwise impossible for systemic chemotherapy to provide a
meaningful effect for PMP. CRS and perioperative HIPEC do not guarantee a successful
remission of this cancer, and, in reality, relapse is common for these patients.
1.5 Chemotherapeutics Used in PMP
Chemotherapeutic drugs are varied and vast in numbers. However, to date there
has not been an exhaustive study on the effects of common chemotherapy drugs on PMP
derived cancers. That was the focus of this study. Four drugs were chosen due to their
prevalence of use for gastrointestinal or colorectal cancers (CRC).
Mitomycin C (MMC) is a commonly used therapeutic in HIPEC chemotherapy
procedures. MMC causes a lethal crosslinking of complementary DNA strands, and is an
effective non-growth specific antibiotic agent 63. However, it is the compound’s relative
sensitivity to carbon monoxide or oxidative stress that allows for a more selective focus
in the treatment of cancer. Due to the lack of both carbon monoxide and oxygen, solid
tumors are a prime location for the generation and maintenance of reactive drug
metabolites from MMC 30. At a high concentration MMC is able to kill cells in normoxic
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conditions, and this is of critical importance when determining an appropriate therapeutic
dose 33.
The mechanism of 5-Fluorouracil (5-FU) is not completely understood; however,
it is assumed that the introduction of therapeutically active metabolites interferes with the
synthesis of DNA during the S phase. 5-FU is an antimetabolite, and, along with the
folate cofactor, binds to thymidylate synthase. This in turn inhibits the formation of
thymidylate, and inhibits the synthesis of both DNA and RNA 63. 5-FU has a long history
of use in various types of cancers: bladder, CRC, and skin cancers amongst others. 5-FU
is used in specialized manners like HIPEC as part of multi drug treatment plans yielding
promising results for patient 5 to 10-year survival ratings. With respect to advanced CRC,
5-FU as the primary drug is shown to have a 10-15% survival rate, yet when combined
with Oxaliplatin boosts survival rates up to 40% 18.
Oxaliplatin (Oxp) is a widely used chemotherapy agent used for CRC, advanced
CRC, gastric, and bladder cancers 63, 12, 22. In vivo, Oxp is metabolized into active
metabolites which bind to both guanine and cytosine nucleotides in DNA. This binding
leads to crosslinking within the DNA, and inhibits nuclear functionality within the cell 63.
Oxp is a platinum-based compound and, while its therapeutic effects cannot be argued, it
is plagued with hypersensitivity reactions. These reactions can vary from mild, such as
chills or fever, to more severe like thrombocytopenia 2, 15. Numerous studies show
effective means to mitigate Oxp induced toxicities. Oxp, while effective as a solitary
drug, is often used as part of a multi-drug treatment for CRC known as FOLFOX.
FOLFOX is a combination therapy consisting of 5-Fluorouracil, leucovorin, and
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Oxaliplatin. FOLFOX is shown to be more effective than Oxaliplatin monotherapy, and
with less toxicity 22.
Irinotecan is a chemotherapy agent commonly prescribed for CRC, pancreatic and
lung cancer 10. Irinotecan is a pro-drug transformed, in vivo, to SN-38 which is the active
cytotoxic agent. SN-38 is 100-1000 times more potent than the un-modified Irinotecan,
and is the mitigating factor responsible for dose limiting toxicities 63, 10, 22, 28. Irinotecan
and SN-38 impact the cell’s ability to replicate DNA by binding to the topoisomerase I
DNA complex. Topoisomerase I mitigates supercoiling of DNA post replication fork by
cleaving a single strand. This chemotherapy agent, topoisomerase I, and DNA super
complex cause lethal double strand breaks within the cell DNA. These double strand
breaks lead to cellular apoptosis 28. Irinotecan is a part of FOLFOXIRI, a derivative of
FOLFOX which contains 5-FU, leucovorin, oxaliplatin, and Irinotecan. This treatment is
extremely effective although inducing neutropenia and peripheral neurotoxicity 52, 22.
1.6 Mucinous Colorectal Cancer
In addition to true PMP cancers, this study also includes 2 mucinous colorectal
cancers that had invaded the peritoneal cavity of patients: CO5-1 and CO9-1. Visually,
both the PMP cancer and mucinous adenocarcinoma appear similar. Mucinous colorectal
adenocarcinomas typically produce large quantities of MUC2 and MUC5AC mucins 59, 39,
23

. Mucinous colorectal adenocarcinomas was found to be present in 38.5% of CRC

patients in the Leopoldo study, but statistics vary through literature34. The location of the
mucinous CRC tumor is predicative of severity of outcomes, with more distal colon
locations yielding a far bleaker prognosis. There is differential gene expression between
the proximal and distal colon MUC, and this leads to distinct histological features34. The
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CO9-1 biopsy was removed from the cecum, while the CO5-1 original biopsy was
removed from the sigmoid colon of PMP patients.
1.7 Experimental Intent
These experiments were designed from the historical precedence of
chemotherapeutics used as treatment for GI or CRC localized cancers. The intention of
this study is to provide dose response curves to PMP cell line cancer, and determine the
LD50 of their interactions. A multi-drug therapy was devised to test the synergy between
5-FU and Irinotecan and to provide insight for future experimentation with other multidrug therapies. These cancers were acquired from patients who suffer from unique
instances of PMP through Mercy Medical Center in Baltimore, Maryland.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Cell Culture
In this study 5 cancers were managed and tested: CO5-1, CO9-1, PMP 501-1,
PMP 457-2, and ABX 023-1. The patients, prior to biopsy removal, had no history of
either radiation therapy or HIPEC. Within this study the prefix ABX designates that the
PMP cell line was obtained from a patient who underwent antibiotic therapy with
lansoprazole, amoxicillin, and clarithromycin. MS CO5-1 F3 (CO5-1) was a human
mucinous adenocarcinoma cell line xenografted into an immune deficient mouse model
and subsequently cultured in vitro. CO5-1 was removed from the mucin within the
peritoneal cavity, but originated from the sigmoid colon of a 61-year-old female patient.
The patient had undergone 2 separate cycles of FOLFOX/Avastin chemotherapy prior to
biopsy removal. CO9-1 was a moderately differentiated mucinous adenocarcinoma from
a 48-year-old male patient, originating from the cecum but removed from the omental fat.
The patient received three chemotherapy cycles: FOLFOX, Xeloda/Oxaliplatin, and
FOLFOX/Avastin prior to biopsy. PMP 501-1 was removed from the peritoneal cavity of
a 70-year-old female patient. Prior to biopsy, this patient also had no history of
chemotherapy. PMP 501-1 was a DPAM type PMP cancer that was well differentiated.
This cancer had evidence of extracellular mucin organization. PMP 457-2 was a DPAM
type PMP cancer removed from the peritoneal cavity of a 53-year-old male patient with
no history of chemotherapy. In addition to extracellular mucin organization, there was
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evidence of strips of mucinous epithelium within the sample. ABX 023-1 was a PMCA-S
type PMP cancer which was moderate to poorly differentiated. The biopsy was removed
from the pelvic peritoneum of a 40-year-old male patient, with evidence of fibrous tissue
in organizing extracellular mucin. Prior to biopsy this patient had undergone a cycle of
FOLFOX/Avastin.
Each PMP cancer cell line was cultured in T25 flasks and passaged every 3 days.
The flasks that had reached 90% confluency, after a visual inspection utilizing light
microscopy, were subcultured into new T25 flasks. The T25 flasks were stored in an
environmentally controlled incubator which maintains total atmospheric CO2 at 5% and
37°C. The used media was aspirated and adherent cells rinsed with 3ml of 1x Phosphate
Buffered Saline (PBS) solution. The 1x PBS was then aspirated, and 0.6mL of trypsin
(0.05% trypsin/EDTA from Thermo Fisher) was added to the T25 flask. Each flask was
then returned to the incubator. After 4 minutes, the flasks were removed from the
incubator and checked for adequate detachment. After confirming detachment of the
monolayer, 2.7mL of PMP medium are added to each T25 flask. The PMP medium was a
solution of: Corning Ham’s F12 Nutrient Mixture (Ref 10-020-CV), 10% heatinactivated fetal bovine serum, 10µg/ml recombinant human insulin, and 1x
ampicillin/streptomycin. A mechanical pipette was used to de-clump the cells and
resuspend the cells and 1mL of this solution was added to the new T25 flasks containing
5 mL growth medium.
The cancer lines that had not achieved confluency were fed with 6 mL of new
PMP. These cell lines are visually inspected each week to determine the degree of
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confluency, and once confluent the cancer cells are transferred into new T25 flasks
utilizing an identical protocol as above.
2.2 Cell Counting
The cancer cell lines were counted prior to any experimentation. 30uL of trypan
blue was added to a sterile microcentrifuge tubes containing detached tumor cells. The
microcentrifuge tube is mixed by tapping, and 10uL of the mixed solution is pipetted
onto a hemocytometer. The total number of cells counted within the hemocytometer were
multiplied by 2, divided by four, and then multiplied by 10000. The desired cell count in
the experiment was then divided by this calculated number.
2.3 Plating PMP Cancer Cell Lines
Each well of the 96 well plate was calculated to a combined total volume of
100uL. This is a combination of both the PMP cell line and PMP Media. To initially plate
each 96 well plate, the cancer cell lines were calculated, as previously stated, to
determine the appropriate volume for each well. This volume was then subtracted from
the total volume of 100uL to determine the volume of PMP media. Using a multichannel
pipette, the appropriate volume PMP media was added to each well. Subsequently, the
appropriate volume of cancer cell solution is added to each well. Once plated, the time
was recorded and the plate incubated in an atmosphere of 5% CO2 at 37°C for 24 hours.
This time table was designed to allow the cancer cells to attach to growth plate on the
bottom of the well and proliferate to the desired cell count.
2.4 Dosage and Treatment
At the end of 24 hours, the 96 well plate was removed from the incubator and
visually inspected under a light microscope to verify cell attachment at the bottom of the
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well. The media within each well was aspirated with the vacuum set up, with careful
attention to not disrupt the cell attachment at the bottom of each well. Four
chemotherapeutic drugs were tested across a range of dosages: Mitomycin C (MMC), 5Flurouracil (5-FU), Oxaliplatin (Oxp), Irinotecan, and 5-FU/Irinotecan combination.
DMSO was the vehicle used to dissolve MMC, 5-FU, and Irinotecan. A vehicle control
was created in these specific cell lines to monitor DMSO toxicity to the cancer cells. Sybr
green was also added to each dose to measure cell proliferation. Sybr green was prepared
in a 10% concentration solution for these experiments with PMP media + antibiotics.
Each well received 50ul of the appropriate cancer therapeutic solution including all
control wells. Each PMP cell line were subjected to 48 hour treatments with each tested
chemotherapy, and then subsequently scanned for dsDNA and ATP values using the
Biotek Synergy 2 microplate reader. The chemotherapy agents were obtained through
Caymen Chemical Ann Arbor, Michigan.
Initial experiments used Mitomycin C (MMC) concentrations ranging from
1µg/ml-100µg/ml. Based on these results, concentrations between 1 µg/ml and 5 µg/ml
were used for subsequent experiments. MMC was prepared in both a 1mg/ml and
10mg/ml stock solution for these experiments using 100% DMSO as a solvent. The low
dose experimentation was performed under both 50000 and 40000 cell counts.
The initial 5-Fluorouracil (5-FU) experiment dose concentrations ranged from
500nM to 500µM. Based on these results, the final dose concentrations were 35µM to
500µM. DMSO was prepared in a 1.3% concentration solution from 100% DMSO using
PMP media + antibiotics. 5-FU was prepared in a 1mM concentration using a 10mg/ml 5-
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FU stock solution (76.9mM) and PMP media. The 5-FU stock solution was prepared
using 100% DMSO as a solvent.
Oxaliplatin (Oxp) dose concentrations ranged from 40µM to 120µM. The
Oxaliplatin stock solution was prepared using deionized water creating a 5mg/ml solution
(12.5849mM).
Irinotecan dose concentrations ranged from 20µM to 100µM. The Irinotecan
stock solution was prepared using 100% DMSO as the solvent. Ultimately, the Irinotecan
stock solution was 20mg/ml (34.089mM).
The 5-FU/Irinotecan combination trial had one range of drug concentrations. PMP
cell lines were initially treated for 6 hours with 100 µM 5-FU. A 5-FU DMSO vehicle
control was created in accordance with the 5-FU protocol. After 6 hours, the 5-FU
treatment was aspirated from the 96 well plate with a vacuum set up with the exception of
the 5-FU DMSO vehicle control. The 5-FU DMSO vehicle control was allowed to remain
through the entire 48 hours. Irinotecan was then added to the 96 well plate in accordance
with the Irinotecan protocol with the exception of the 20 µM concentration. Background
control wells were created with both vehicle controls. The Irinotecan treatment continued
for 42 hours in order to mirror the 48-hour treatment performed with previous dose
response curves.
2.5 dsDNA Assay
. At the end of the experiment, the 96 well plate was removed from the incubator
and wrapped in aluminum foil for transport to the microplate reader. The 96 well plate
was inserted into a Biotek Synergy 2 microplate reader. The program read fluorescence
within the 520nm wavelength of light and calculated a total fluorescent value per well.
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The plate was then wrapped in aluminum foil for transport back to the laboratory for
additional testing. The background control well numbers were averaged, and then
subtracted from each raw number to provide the data for analysis. The numbers were
normalized to the vehicle control well to calculate dsDNA increase/decrease on
Microsoft Excel. The data was then entered into Graph Pad Prism, for statistical analysis
and graphing.
2.6 ATP Assay
50µl of Promega BacTiter-Glo (BTG) was added to each well of the 96 well plate
in a 1:1 volumetric ratio. After the addition of BTG the plate was once again covered in
aluminum foil. The covered plate was then mixed for 5 minutes at a moderate pace with
an orbital shaker. The plate was then read by the Biotek Synergy 2 microplate reader
which measured the luminescence within each well to assign values to the ATP content.
The background control well numbers were averaged, and then subtracted from each raw
number to provide the data for analysis. The numbers were equalized to the vehicle
control well to show proportionality of ATP values on Microsoft Excel. The data was
then entered into Graph Pad Prism, where all statistical analysis and graphing took place.
2.7 Proliferation Trials
The proliferation experiment evolved through two unique cell counts utilizing an
identical procedure: 40,000 and 10,000 cell counts. Each of the PMP cell lines were
plated with the appropriate initial cell count using the same methods as outlined earlier. A
96 well plate was prepared with 5 distinct cancer cell lines: PMP 501-1, PMP 457-2,
CO9-1, CO5-1, and ABX 023-1. Each cell line was analyzed in triplicate. The plate was
labeled with the time of plating, and a background control well was created using only
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PMP media + antibiotics. Each day had a unique control well to verify the sterility of the
PMP medium. The 96 well plate was then stored for 24 hours in an environmentally
controlled incubator at the same parameters as previously mentioned. Every 24 hours for
5 (40,000 cell experiment) or 6 (10,000 cell experiment) the 96 well plate was removed
from the incubator and 100µl BTG was added in a 1:1 ratio with the initial well volume.
The 96 well plate was then wrapped in aluminum foil, and placed on an orbital shaker at
a moderate speed for 5 minutes. The plate was then read by the Biotek Synergy 2
microplate reader utilizing the same ATP program as utilized in the ATP assay. Each set
of triplicates indicated 24 hours of cell proliferation, and for each day this protocol was
repeated. At the end of the 6-day experiment, the numbers were normalized to the 24
hour time point of ATP values with the average background value subtracted from the
raw data values on Microsoft Excel. The normalized numbers were then entered into
Graph Pad Prism where all subsequent statistical analysis and graphing took place.
2.8 Statistical Analysis
For each chemotherapy experiment t-Tests were performed between the control
and subsequent concentration points. For the 10,000 cell growth experiment t-Tests were
performed between the 24 hour baseline and each subsequent 24 hour point. P values
were calculated and displayed on each graph where appropriate, using p<0.05 as the cut
off for significance. SEM was calculated to provide error at both the control and for each
concentration point for the chemotherapy experiments.
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CHAPTER 3
RESULTS
3.1 40,000 and 10,000 Cell Count Growth Experiment
The first growth experiment was initially seeded in each well with 40,000 cells
(Fig 3.1). Over 72 hours ATP values were unremarkable with the exception of PMP 4572 which had a recorded 26.2% (±18.4%) increase from control. ABX 023-1 had the
largest growth in this experiment by 96 hours with a 38.7% (±10.7%) increase in ATP
values. From 96 to 120 hours each of the cancers had a reduction in ATP values. The
most extreme reduction occurred with PMP 457-2, which fell 52.1% between 96 and 120
hours. CO9-1 ATP values at 120 hours were the smallest in the experiment, a 43.8%
(±3.87%) reduction from control. A second growth experiment was devised with an
initial density of 10,000 cells per well. Over 72 hours ATP values consistently increased
for all cancers (Fig 3.2). ABX 023-1 ATP values increased more than 2-fold increase by
72 hours and reached peak growth by 96 hours, with a 147.8% (±28.7%) increase from
baseline values (Fig 3.3). At 120 hours, however, ABX 023-1 suffered a large drop in
ATP values falling 72.9% (±16.7) below the baseline 24 hour mark. At the 144 hour
mark ATP values continued to decrease, a 82% (±12.4%) reduction from control.
Significance was present at each time point in the experiment. PMP 457-2 consistently
measured increasing ATP values until the 72 hour mark, measuring peak growth as a
89.6% (±4.37) increase from baseline (Fig 3.3). From 96 hours ATP values fell but
maintained baseline levels, and by 144 hours these values fell 6.63% (±8.1%) below
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control. Significance was observed from 48 to 96 hours. CO9-1 ATP values increased
until reaching peak growth at 72 hours, a 96.7% (±12.9%) increase from control (Fig
3.5). ATP values were maintained through 96 hours, before falling from control in excess
of 90% at 120 hours, 92.7% (±3.47%), and 144 hours 95.5% (±4.51%). In addition,
significance was present at each time point. CO5-1 ATP values had reached peak
numbers by 72 hours, a 163.6% (±19.6%) increase from control (Fig 3.6). Through 96
hours ATP values remained as a two-fold increase from the baseline, but these values
began to fall by 120 hours with a 45.2% (±5.18%) increase from control. At 144 hours
ATP values fell below that of control, an 8.69% (±3.63%) reduction. Significant
differences were present in this experiment through 120 hours. PMP 501-1 ATP values
rose until 72 hours where it eclipsed a two-fold increase, 105.8% (±2.25%) from control
(Fig 3.7). Beginning at 96 hours and lasting through 120 hours, ATP values gradually fell
to a 37.9% (±28.1%) increase compared to baseline. At 144 hours, however, these values
precipitously fell 60.9% (±23.0%) from control values. Significant difference was present
through 96 hours in this experiment.
3.2 Mitomycin C 50,000 Cell Count Experiment
Of the five cancers, only ABX 023-1 and PMP 501-1 showed an average ATP
increase from control at 1µg/ml MMC: 44% (±38.1%) and 10.3% (±24.8%) respectively
(Fig 3.8). PMP 457-2 ATP values declined significantly at 2µg/ml and higher
concentrations of MMC (Fig 3.9). At the highest concentration PMP 457-2 had a 77%
(±10%) reduction from control. PMP 501-1 ATP values consistently declined over the
dose curve, reaching a 63.6% (±18.8%) reduction from control at 5µg/ml (P<0.05 vs
control) (Fig 3.10). ABX 023-1 ATP values dipped below that of control at
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concentrations of MMC greater than 4µg/ml (Fig 3.11). Significant difference was only
observed at 5µg/ml, with a 52.5% (±16.8%) reduction from control. At concentrations
greater than 1µg/ml MMC, CO9-1 ATP values are below that of control (Fig 3.12).
Significant difference is only present at 3µg/ml and greater concentrations, and ATP
values fell below 50% of control by 4µg/ml. CO5-1 had consistently declining ATP
values as the concentration of MMC increased, with significant difference present at
3µg/ml and greater concentrations (Fig 3.13). ATP values were below 50% of control by
4µg/ml, and at maximum concentration CO5-1 had a recorded 60.6% (±13.3%) reduction
from control.
3.3 Mitomycin C 40,000 Cell Count Experiment
ATP values for each of the 3 tested cancer cell lines consistently fell as the
concentration of MMC increased (Fig 3.14). Additionally, by 3µg/ml MMC, each of the
cancer ATP values was below 50% of its control value. A significant difference was
observed at each drug concentration for ABX 023-1, and at maximum concentration there
was a 66.5% (±10.2%) reduction from control (Fig 3.15). PMP 501-1 ATP values were
the lowest at 4µg/ml, a 74.1% (±7.02%) reduction from control, but slightly increased by
4% at maximum concentration (Fig 3.16). Significance was present at concentrations of
2µg/ml and greater. (Fig 3.17). The ATP values for CO5-1 remained consistent from 34µg/ml, but had the largest total reduction at maximum concentration 80.6% (±7.68%)
from control (Fig 3.17). Significance was present at each drug concentration.
3.4 5-Fluorouracil Experiment
ATP values for the 5-FU experiment trended negatively as the dose increased (Fig
3.18). CO5-1 ATP values slightly fell at 30µM, a 8.77% (±12.2%) reduction, and
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maintained these values through 75µM 5-FU (Fig 3.19). At the 100µM concentration
ATP values began their descent but did not fall below 50% of control until 500µM 5-FU.
At maximum concentration there was a recorded 64.8% (±13.8%) reduction from
baseline, and significant difference was present at concentrations of 100µM and greater.
PMP 501-1 ATP values fluctuated within 6% of baseline through 75µM 5-FU (Fig 3.20).
At 100µM ATP values fell 11.3% (±15.4%), and these values were effectively
maintained through 300µM. 5-FU. PMP 501-1 had a 36% (±19.3%) reduction in ATP
values from the control by 500µM, but there was no significance present within this
interaction. ABX 023-1 ATP values consistently decreased throughout the 5-FU
experiment (Fig 3.21); however, these values did not fall below 50% of control until
500µM. At maximum concentration, a significant reduction (p<0.0001) of 72.5%
(±11.4%) from the control was observed. PMP 457-2 ATP values fluctuated from
baseline through 100µM 5-FU, with a maximum increase of 8.68% (±4.89%) at 75µM
(Fig 3.22). PMP 457-2 at maximum concentration had a significant reduction (p<0.0001)
of 47.1% (±20.3%) from control. ATP values for CO9-1 trended negatively through the
5-FU dose curve (Fig 3.23). These values fell below 50% of control at 300µM and
500µM, 50.7% (±14.4%) and 62.0% (±13.3%) respectively, and significant reductions
were present at both concentrations.
3.5 Oxaliplatin Experiment
Four of the five tested cancers had a negative trend for ATP values as the
concentration of Oxp increased, and only CO9-1 ATP values were in excess of baseline
values (Fig 3.24). PMP 457-2 average ATP values never fell below 50% of control (Fig
3.25). The lowest recorded average ATP values occurred at 60µM, a 43.8% (±8.29%)

20

reduction, and 80µM, a 43.8% (±7.57%) reduction. Significant differences were observed
at each tested concentration. CO5-1 values fell below 50% of control at both 100µM and
120µM, and by 120µM Oxp had a 66.7% (±13.5%) reduction (Fig 3.26). Significant
differences were also present at each tested Oxp concentration. CO9-1 ATP values only
fell below control at 40µM, measured as a 20.8% (±11.1%) reduction (p=0.0232) (Fig
3.27). At 100µM Oxp, ATP values were the largest in the experiment with a 11.7%
(±20%) increase from control. It is important to note the large variance observed in the
data for CO9-1. As the concentration of Oxp increased in this experiment, the overall
range of measured ATP values also increased. ABX 023-1 had significant difference
present at every concentration of Oxp, and ATP values fell below 50% of control at
concentrations of 80µM and greater (Fig 3.28). At both 100µM and 120µM the ATP
values were in excess of a 70% reduction from control, 72.6% (±6.26%) and 78.8% (±
5.53%) respectively. Significant difference was present (p<0.0001) for each
concentration point for PMP 501-1, however at no point were average ATP values below
50% of control (Fig 3.29). At maximum concentration, PMP 501-1 ATP values were
measured as a 49.3% (±8.55%) reduction from control.
3.6 Irinotecan Experiment
Three of the five tested cancers had average ATP values measured in excess of
control for the entirety of this experiment (Fig 3.30). PMP 501-1 ATP values consistently
increased until 80µM which was the maximum growth observed in this experiment as a
73.6% (±14.2%) increase from control (Fig 3.31). At maximum concentration ATP
values were at their lowest point for this cancer, at a 38% (±22.2%) increase from
control. Significant differences were observed at concentrations of 80µM and below.
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ABX 023-1 ATP values were in excess of control at concentrations between 40µM and
80µM however, peak ATP values were observed at 60µM with a 15% (±11.9%) increase
(Fig 3.32). Average ATP values began to decrease again at 80µM, and by 100µM had
reduced by 65.8% (±16.8%) as compared to the control. A significant difference was also
only present at the maximum concentration of 100µM Irinotecan. CO9-1 had the largest
measured growth in this experiment eclipsing a twofold increase in average ATP values
at both 60µM and 80µM Irinotecan (Fig 3.33). Average ATP values continuously
increased from control to 80µM Irinotecan where peak growth was observed as a 114%
(±28.7%) increase. ATP values begin to reduce again by 100µM, but still were a 93%
(±36.2%) increase from control. Differences were significant at each concentration point
in this experiment. CO5-1 average ATP values consistently increased until 60µM a
28.2% (±8.27%) increase from control (Fig 3.34). ATP values were effectively
maintained through 80µM before falling below control at 100µM, a 30.6% (±16.4%)
reduction from control. Significant reductions were observed at concentrations between
40µM and 80µM Irinotecan. PMP 457-2 recorded average ATP values were in excess of
control for the entirety of this experiment (Fig 3.35). These values fluctuated until 60µM
where peak growth was observed as a 37.8% (±12.3%) increase from control. Beginning
at 80µM there is a reduction of ATP values, before falling to the smallest growth
recorded at 100µM Irinotecan as a 7.38% (±17.8%) increase from control. Significant
differences were only observed at the 60µM and 80µM concentrations.
3.7 Combination Experiment
ATP values for the combination experiment were in excess of a 30% reduction in
control values (Fig 3.36). PMP 501-1 values fell by 35.4% (±3.77%) at 40µM Irinotecan
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(Fig 3.37). These ATP values fluctuated within 10% as the concentration of Irinotecan
increased, and by the maximum Irinotecan concentration fell 45.0% (±7.55%) as
compared to the control. Significant differences were observed at each concentration
point. CO5-1 average ATP values fell below 50% of control at concentrations of 80µM
and 100µM Irinotecan, with a 79.2% (±4.98%) reduction from control at 100µM (Fig
3.38). Significant differences were obtained at each concentration point. CO9-1 initial
ATP values dropped 46.2% (±5.63%) at 40µM Irinotecan, and the average values
fluctuated within 6% for each of the subsequent concentrations (Fig 3.39). Peak growth
was observed at 80µM Irinotecan as a 40.8% (±4.22%). Significance was present at each
concentration point as well. PMP 457-2 ATP values consistently decreased as the
Irinotecan concentration increased (Fig 3.40). Initially at 40µM there was a 40.0%
(±2.11%) reduction from control, and by 100µM ATP values had further declined to
64.6% (±3.13%) decrease. Significance was also present at each concentration point for
this interaction. ABX 023-1 values fell by 44.6% (±7.5%) at the 40µM Irinotecan
concentration, and fluctuated within 6% as the concentration increased (Fig 3.41). ATP
values by 100µM had reduced from the control well by 49.4% (±10.8%). Significant
difference was observed at each concentration point.
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Figure 3.1 PMP cell line growth experiment. 40,000 cell count.
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Figure 3.2 PMP cell line growth experiment. 10,000 cell count.

104

124

144

ABX 023-1 10000 Cell Growth Experiment

Relative Change

4

p=0.0077
p=0.0296
p=0.0269

3
p=0.0009

2

p=0.0070

1
0
24 48 72 96 120 144

Hours After Plating

Figure 3.3 ABX 023-1 average ATP values. 10000 cell count growth trial.
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Figure 3.4 PMP 457-2 average ATP values. 10000 cell count growth trial
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Figure 3.5 CO9-1 average ATP values. 10000 cell count growth trial.
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Figure 3.6 CO5-1 average ATP values. 10000 cell count growth trial.
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Figure 3.7 PMP 501-1 average ATP values. 10000 cell count growth trial.
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Figure 3.8 PMP Cell lines treated by MMC therapy at 50,000 cell count.
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Figure 3.9 PMP 457-2 ATP values as treated by MMC 50,000 cell count
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Figure 3.10 PMP 501-1 ATP values as treated by MMC 50,000 cell count
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Figure 3.11 ABX 023-1 ATP values as treated by MMC 50,000 cell count

CO9-1 ATP Values, 50000 Cell Count / MMC
1.5

p=0.0004
p=0.0009

Relative Change

p=0.0058

1.0

0.5

0.0
0

1

2

3

4

5

MMC Concentration (µg/ml)

Figure 3.12 CO9-1 ATP values as treated by MMC 50,000 cell count
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Figure 3.13 CO5-1 ATP values as treated by MMC 50,000 cell count.
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Figure 3.14 PMP cell lines treated by MMC therapy. 40,000 cell count trial
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Figure 3.15 ABX 023-1 ATP values as treated by MMC 40,000 cell trial
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Figure 3.16 PMP 501-1 ATP values as treated by MMC 40000 cell trial
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Figure 3.17 CO5-1 ATP values as treated by MMC 40000 cell trial.
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Figure 3.18 PMP Cell lines treated with 5-FU therapy
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Figure 3.19 CO5-1 ATP values as treated by 5-FU
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Figure 3.20 PMP 501-1 ATP values as treated by 5-FU
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Figure 3.21 ABX 023-1 ATP values as treated by 5-FU
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Figure 3.22 PMP 457-2 ATP values as treated by 5-FU
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Figure 3.23 CO9-1 ATP values as treated by 5-FU.
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Figure 3.24 PMP cell lines treated by Oxp therapy.
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Figure 3.25 PMP 457-2 ATP values as treated with Oxp
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Figure 3.26 CO5-1 ATP values as treated with Oxp
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Figure 3.27 CO9-1 ATP values as treated with Oxp
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Figure 3.28 ABX 023-1 ATP values as treated with Oxp
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Figure 3.29 PMP 501-1 ATP values as treated with Oxp.

43

PMP Cell Lines Irinotecan Treatment
2.5

44

Relative Change

2

1.5

CO5-1
CO9-1
PMP 501-1

1

PMP 457-2

ABX 023-1

0.5

0

0

10

20

30

40

50

60

Irinotecan Concentration (µM)

Figure 3.30 PMP cell lines treated by Irinotecan therapy
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Figure 3.31 PMP 501-1 ATP values as treated with Irinotecan
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Figure 3.32 ABX 023-1 ATP values as treated with Irinotecan
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Figure 3.33 CO9-1 ATP values as treated with Irinotecan
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Figure 3.34 CO5-1 ATP values as treated with Irinotecan
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Figure 3.35 PMP 457-2 ATP values as treated with Irinotecan.
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Figure 3.36 PMP cell lines treated by 5-FU/Irinotecan combination therapy
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Figure 3.37 PMP 501-1 ATP values as treated by 5-FU/Irinotecan combination
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Figure 3.38 CO5-1 ATP values as treated by 5-FU/Irinotecan combination
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Figure 3.39 CO9-1 ATP values as treated by 5-FU/Irinotecan combination
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Figure 3.40 PMP 457-2 ATP values as treated by 5-FU/Irinotecan combination
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Figure 3.41 ABX 023-1 ATP values as treated by 5-FU/Irinotecan combination.
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Table 3.1 Results summary table: Cell type, doubling time, and LD50

Cell Line

Type

Doubling Time

MMC 50,000

MMC 40,000

5-FU LD50

Oxaliplatin

Irinotecan

Combination

(hr)

LD50 (µg/ml)

LD50 (µg/ml)

(µM)

LD50 (µM)

LD50 (µM)

Treatment
(µM)

CO5-1

Colon: sigmoid

54.5

3.78

68.6

4.16

67.2

4.13

76.7

2.85*

67.3

5.61

2.68*

349.4*

89.7

451.4

61.71

363.5*

High

High

223.6

738.3

100.5

High

96.3

582.8

129.2

High

75.2

369.8*

68.3

210.1

90.5

mucinous
adenocarcinoma

CO9-1

Colon: cecum
mucinous
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adenocarcinoma
moderately
differentiated

PMP 501-1

DPAM, well

3.07*

differentiated

PMP 457-2

DPAM, well
differentiated

ABX 023-1

PMCA-S
moderate to poorly
differentiated

3.02*

CHAPTER 4
DISCUSSION
Pseudomyxoma peritonei is a rare condition, and the diagnosis is confirmed late
in the development of the disease. At this time, early detection of this condition is
difficult and is rarely achieved. Patients with PMP typically do not raise concerns to their
physicians until they notice their abdomen growing rapidly and they experience
gastrointestinal distress. In addition, PMP can be discovered by surgeons performing an
unrelated procedure in the abdominal area44, 40. Chemotherapy retains an integral role in
the treatment of PMP, and our study aims to add additional information to an evolving
field of study. However, chemotherapy alone does not force this condition into total
clearance or remission. Research shows that the combination of bulk tumor removal and
HIPEC as a paired treatment yield far better results than either procedure on their own 56.
This bulk removal of cancerous epithelial cells, solid tumors, and mucin is related
directly to the unique growth parameters of each cancer. In cases where CRS and HIPEC
are unsuccessful, or when patients are inoperable, patients are subjected to more
traditional systemic chemotherapy. PMP tumors are variable in cellularity and
differentiation state, and the tested PMP cancers in this study reflects that. In this study,
in addition to direct PMP cancers, mucinous colorectal cancers that have invaded the
peritoneal cavity are also included. In addition to providing novel dose response curves to
untested variants of PMP cancer, we explored the growth rates of each cancer in an
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attempt to categorize the rate of proliferation and provide distinct evidence to
chemotherapy sensitivity.
4.1 Growth Experiments
The chemotherapies utilized in this study encourage apoptosis of cells as they
progress through the cell cycle with one exception; MMC is a non-cell cycle phase
specific chemotherapy. The growth rates of the cancers that were tested can give us a
glimpse into the rate of proliferation, and when that weakness can be exploited by
therapy. These cancers were subjected to two growth experiments through the course of
this study. Each growth experiment was initially seeded in 96 well microplates with
differing cell counts: 40,000 and 10,000 cells per well. 10,000 cell doubling rates for each
PMP cell line were calculated and are summarized in Table 3.1. Doubling rates for the
40,000 cell experiment could not be calculated due to the lack of exponential growth
observed through the experiment. The 40,000 cell experiment initial raw ATP values
were roughly 5 times larger than ATP values for the 10,000 cell experiment. This is
relevant for discussion because 40,000 cells were the baseline for each chemotherapy
experiment. The observed ATP values at 40,000 cells per well are more indicative of a
solid tumor than at any point in the 10,000 cell experiment. The 40,000 cell experiment
also shows limited proliferation across 120 hours. It is, however, important to note that
by 72 hours each cell line was able to at a minimum maintain baseline values. These
results confirm that ATP reduction through the course of each chemotherapy trial was not
related to natural cell death.
Doubling time was calculated for each cancer in the 10,000 cell count growth
experiment. However, significant ATP reduction was observed after 96 hours for 3 out of
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the 5 cancers. Total proportionality of growth or initial raw ATP values show no
correlation with this ATP reduction. It is theorized that a number of factors influenced the
reduction of ATP values in the 10,000 cell growth experiment. Each cancer which
experienced this large ATP reduction were uniquely affected by medium chemistry.
Growth medium was unaltered through the course of experimentation to prevent
disruption of growth and unintentional cell removal. This seemed to not significantly
impact growth through 72 hours for the tested PMP cell lines, but later in the trial 3 of the
5 cell lines showed significant reductions in ATP values. It is possible that medium
toxicity greatly affected cell health as the trial progressed. Toxic byproducts could have
inhibited cellular growth through pH or salinity overloading. It is also possible that
medium nutrition was exhausted by the 96-hour mark, and the lack of available nutrients
impacted cellular growth and survival of the cancer cells post 96 hours. Cancers such as
PMP 457-2 and CO5-1 seem uniquely resistant to toxicity and nutrient deficiency in the
media. This could imply that CO5-1 and PMP 457-2 are able to sustain themselves in
more toxic environments than the other cancer cell lines. Their ability to maintain ATP
values through 144 hours is conducive to solid tumor development located in sparsely
vascularized areas within the peritoneal cavity. These growth experiments should be
replicated with the addition of daily media changes. This change in protocol would
remove the inhibitory effects of medium toxicity, supply necessary cellular nutrition for
continued growth, and should be compared to our study to further expand PMP cellular
growth literature.
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4.2 Sensitivity to Mitomycin C
MMC has been a mainstay for treatment of CRC for some time, and
pharmacokinetic studies have tested clinical dose MMC therapy as both a solitary agent
as well as part of a combination therapy. The Hartigh study tested 36 patients utilizing
MMC as part of a multi-drug therapy. Peak plasma concentrations were within 0.4 and
3.2 µg/ml 11. MMC has been used in the past as both a solitary agent for CRC patients
and as part of HIPEC utilizing fluoropyrimidine agents such as 5-FU 28. The results from
our study show that every PMP cell line had sensitivity to MMC in the 50,000 cell trial.
In this trial only one PMP cancer had a calculated LD50 in excess of the tested
concentrations. ABX 023-1 (Fig 3.4) LD50 was calculated as 5.61 µg/ml, and does not
fall within acceptable clinical parameters. However, when tested at the 40,000 cell count
ABX 023-1 (Fig 3.8) LD50 falls to 3.02 µg/ml. This value does, in fact, fall within
clinical MMC plasma concentrations. Significant reductions in ATP values for the 40,000
cell trial were observed at every MMC concentration. This also holds true for both PMP
501-1 and CO5-1. Within the 50,000 cell trial, the calculated LD50 for either of these
PMP cell lines lie in excess of clinical plasma concentrations (Fig 3.3) (Fig 3.6), but both
respond favorably at a smaller cell count, 3.07 µg/ml (Fig 3.9) and 2.68 µg/ml (Fig 3.10)
respectively. The data showed that cellular density within the wells yielded dramatic
differences in MMC concentrations necessary to suppress cellular proliferation. ABX
023-1 was the most affected by the reduction in the number of cells, yielding the largest
differential with respect to LD50 values.
PMP 457-2 showed extreme sensitivity to MMC at 50,000 cells per well (Fig 3.2),
and as such was the only PMP cancer in which the calculated LD50 fell within acceptable
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clinical plasma concentrations. Significant reductions in ATP from the control were
observed at concentrations of 2 µg/ml and higher. Unfortunately, PMP 457-2 was not
available for testing at 40,000 cells per well and it is theorized that this cancer would
follow the observed trend in this study. Additional testing at 40,000 cells per well could
validate this theory, and should be explored in the future along with testing CO9-1. At
50,000 cells, CO9-1 had a calculated LD50 of 4.16 µg/ml which is higher than acceptable
plasma concentrations (Fig 3.5). If CO9-1 also followed the observed trend with respect
to lower cell counts, then it is possible that MMC could be used as therapy for this
variant.
With 10,000 less cells per well each cancer responded very favorably to MMC,
and in practice this data could be implemented with respect to treatment of solid tumors
in PMP cases. Our in vitro experiments of both 50,000 and 40,000 cells per well is more
reminiscent of tumor development, rather than epithelial cell strips often found suspended
in mucin. Solid tumors are not uncommon in patients with PMP. CRS may remove
visible tumors from the interior surfaces of the patient’s peritoneal cavity, but tumors that
are not visible, due to either location of the tumor or buried underneath the tissue surface,
escape this procedure. MMC has a history of use as part of PMP related HIPEC, and our
results show that at high cellular densities MMC is extremely effective. The sensitivity to
both CO and oxygen prevents MMC from full efficacy in densely vascularized regions of
the body. The relative lack of vascularization inside the peritoneal cavity minimizes
oxidative stress that the agent would otherwise encounter. Additionally, lower cell
densities than ones tested might respond even more dramatically. This data is promising
for MMC as a solitary chemotherapy agent for 4 out of the 5 PMP cancers in this study.
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CO9-1 is a prime target for additional testing with multidrug therapy utilizing MMC as
one of the agents.
4.3 Sensitivity to 5-Fluorouracil
5-FU is an integral chemotherapy agent in multi-drug therapeutics such as
FOLFOX and FOLFOXIRI in the treatment of PMP. However, prior to our study these
variants of PMP cancers were absent of specific dose response curves relating to 5-FU as
a solitary agent. 5-FU imparts anti-tumor action through inhibition of thymidylate
formation, and overall inhibition of DNA and RNA synthesis leading to cellular
apoptosis 63. Literature searches revealed a wide range of plasma concentration values
that were clinically relevant for 5-FU. Cmax for 5-FU was calculated as 6.23-55.44µg/ml
(426.19µM) in the Casale study after using clinically relevant doses on patients with
CRC 5. Chemotherapy-induced toxicities are observed in patients regardless of dose
extremity; however, these toxicities are typically amplified at higher doses. The tested
dose concentrations were instituted based on previous cell culture trials and these
concentrations fall in line with clinically relevant plasma concentrations.
Of the tested cancers, only 3 had calculated LD50s which fell within acceptable
clinical plasma concentrations. CO5-1 (Fig 3.12), CO9-1 (Fig 3.16), and ABX 023-1 (Fig
3.14) responded favorably to 5-FU therapy. 5-FU attacks cells during the synthesis phase
of the cell cycle, so it is surprising to see that PMP 457-2 was not uniquely impacted by
this therapy. In the 40,000 cell growth experiment PMP 457-2 was observed to have the
largest increase in growth within 72 hours. The other PMP cancers were recorded to
show minimal comparative ATP value fluctuations during this time period. Both ABX
023-1 and CO5-1 had significantly smaller initial ATP values in the 40,000 cell growth
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experiment as compared to CO9-1, but this also shows no correlation with the calculated
LD50: 369.8 µM, 349.4 µM, and 363.5 µM respectively. It appears that the difference of
cellular density had little impact on the efficacy of 5-FU in this experiment.
5-FU therapy could be an effective solitary agent for chemotherapeutic
intervention in 3 of the 5 tested PMP cancers. The results show significant cell death at
concentrations of 300µM 5-FU and larger. However, to obtain complete, or nearly
complete, cancer cell eradication would require 5-FU concentrations far in excess of safe
plasma concentrations for systemic chemotherapy. The initial plating of PMP cancer cells
aimed for complete confluency within the well, and this density impacted the efficiency
of 5-FU with inducing apoptosis. There is historical precedence of 5-FU used as
treatment for solid state tumors in CRC 5. This brings into focus the combined effort of
fluoropyrimidine agents and other chemotherapies seen often in HIPEC interventions. 5FU is known to have significant, at times debilitating, chemotherapy induced toxicities as
outlined earlier. It is possible to reduce some of the more dangerous toxicities of 5-FU by
pairing it with another CRC agent. FOLFOX, and FOLFOXIRI are shown to be
extremely effective as an intervention for CRC. Hyperthermic administration has been
shown to have no bearing on the efficacy of 5-FU action specifically, however the
addition of numerous chemotherapy agents allows for a multi-pronged attack on PMP
cancer 24. Because of the lack of vascularization inherent within the peritoneal cavity,
physicians are able to administer HIPEC at higher concentrations than would be used in
systemic chemotherapy.
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4.4 Sensitivity to Oxaliplatin
Oxaliplatin is a platinum-based chemotherapy agent used in the treatment of both
CRC and PMP which, while in vivo, is transformed to active metabolites that bind to
both guanine and cytosine nucleotides. This binding leads to lethal crosslinking of DNA
and inhibition of nuclear functionality within the cell 63. Oxaliplatin is an integral part of
the multidrug therapy FOLFOX, utilized as a form of HIPEC. In phase I studies,
Oxaliplatin was administered to patients with various forms of cancer including CRC. A
review of Oxaliplatin pharmacokinetics determined that over a 2-hour treatment, Cmax
values fell between 2.59-3.22 µg/ml (8µM)19.
The results from our study shows that 4 of 5 PMP cell lines responded favorably
to Oxp at concentrations 60 µM and greater (Fig 3.17). The only PMP cancer that lacked
sensitivity to Oxp was CO9-1 (Fig 3.20), and careful analysis of the data reveals an
interesting division within each concentration. An LD50 could not be calculated due to
the average increase in ATP values as concentration increased. Significant difference was
only present between the control well and 40 µM, with higher concentrations yielding no
significant change from control. Each tested Oxp concentration shows two pools of ATP
values, which grow further apart as the concentration increases in the CO9-1 experiment.
The ATP values tend to congregate around 50% of control values and an increase of 50100% compared to control. Roughly 50% of the wells showed sensitivity to Oxp, but it
would be disingenuous to neglect the fact that 50% of wells showed at a minimum an
inability to restrict normal cellular proliferation.
ABX 023-1 showed the most sensitivity to Oxp, with a calculated LD50 of 68.33
µM (Fig 3.21). This particular cancer showed significant ATP reduction at every tested
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Oxp concentration when compared to the control well. Of course, variance within each
concentration is present; however, ATP value densities do not congregate in two unique
pools as seen in CO9-1. It is therefore with some confidence that our study shows
sensitivity with this specific cancer and chemotherapy interaction. PMP 501-1 also
showed a peculiar interaction with Oxp. Each tested Oxp concentration shows a
significant reduction from the control wells, p<0.0001, however average ATP values
show a range of reductions from 42.6% to 51% of the control across the dose range (Fig
3.22). These ATP values show a similar density as the Oxp concentration increases, and
due to the moderate sensitivity observed by the results of the study it is theorized that
PMP 501-1 would yield more promising results with a combination therapy utilizing Oxp
with another agent, or hyperthermic administration of the Oxp agent.
Each calculated LD50 fell in excess of acceptable clinical plasma concentrations.
Dose related toxicities of Oxaliplatin limit the total dose administered to patients
undergoing treatment as systemic chemotherapy. Oxp as administered in this trial as a
solitary agent may not be an effective means to treat these specific PMP cancers. There is
precedence of Oxp utilized as part of a multi drug therapy capitalizing on
fluoropyrimidine agents such as 5-FU 20. Due to time limitations the specific synergy
between 5-FU and Oxp was not explored in this study. In addition, with respect to HIPEC
procedures, chemotherapy temperature was not varied from human body temperature in
this study. HIPEC administers chemotherapy agents at 41°C, but due to the lack of
standardization with HIPEC procedures this temperature can have small variations.
Hyperthermic platinum-based chemotherapies are shown to have a tumor suppressive
effect when utilized in HIPEC. The Helderman study shows a temperature differential of
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1°C above body temperature significantly improves the effectiveness of the platinum
agent. Human colorectal cells respond favorably to increased temperatures, noting a 30%
reduction in cell viability at 43°C which was the highest temperature tested in the study
24

. Our in vitro study maintained a 37°C temperature over 48 hours, and there is the

possibility that short term exposure to hyperthermic Oxp, as seen in HIPEC, might yield
more effective cellular death. The Helderman study has shown that platinum-based
chemotherapies are exceptionally sensitive to temperature with respect to tumor
suppression, yielding more apoptosis through DNA double strand breaks and increasing
the rate of platinum uptake24.
4.5 Sensitivity to Irinotecan and 5-Fluorouracil/Irinotecan
Irinotecan is an anti-tumor chemotherapy utilized as part of treatment protocols
for advanced solid tumor CRC 10. Irinotecan, and the active metabolite SN-38, impact
nuclear functionality by binding to the topoisomerase I DNA complex 5, 10. In the Chabot
paper, Cmax of Irinotecan fell within 1-10 mg/L (16nM) when utilizing a clinically
recommended dose of 100 mg/m2/day. This dose was discovered in a previous phase 1
study of Irinotecan, in which the maximum tolerated dose was determined as 115
mg/m2/day when tested on patients with advanced solid tumors 7, 6.
Irinotecan as the sole chemotherapeutic did not yield promising results (Fig 3.23).
With the exception of ABX 023-1 and CO5-1, all other PMP cell lines showed no
sensitivity to Irinotecan. ATP values showed an average increase as concentrations of
Irinotecan increased to 100 µM, and therefore LD50 could not be calculated for 3 out of
the 5 tested cancers. LD50 for ABX 023-1 was calculated as 210.1 µM, and 451.4 µM for
CO5-1. Both ABX 023-1 (Fig 3.25) and CO5-1 (Fig 3.27) calculated LD50 far exceeds

62

clinical dose ranges utilized in literature. It was reported that in the phase I study,
leukopenia severity increased as the patients were given additional Irinotecan treatment
over time. Chemotherapy related toxicities were seen in 50% of patients exposed to 115
mg/m2/day 6. It is important to note, however, that it has been observed in previous
studies that Irinotecan tends to perform better as a cytotoxic agent in vivo rather than in
vitro 31. This study was entirely in vitro, and should be expanded on in the future to
include possible testing in animal models.
As explored earlier, CRS and HIPEC is the preferred method to attack a diagnosis
of PMP. HIPEC is typically a combination of multiple chemotherapies heated to 40°C
and then administered to a patient perioperatively post CRS. In this study, 5-FU and
Irinotecan was used cooperatively to test the combined efficacy of the drugs. No
chemotherapies in this study were heated to hyperthermic temperatures as part of the
established protocol, but it would be beneficial to validate the previous hyperthermic
chemotherapy studies with these unique PMP derived cancers. If CRS/HIPEC failed, or if
a patient is unable to successfully undergo an operative procedure, physicians utilize
systemic chemotherapy.
Due to the results obtained from the initial Irinotecan experiment, it was
determined that a second experiment was merited. PMP cell line data showed a lack of
inhibition with the exception of CO5-1 and ABX 023-1 showing sensitivity at 100µM
Irinotecan. Irinotecan and 5-FU have been used to treat colorectal cancer as sole agents,
and synergistically in various combinations 65. Dose limiting toxicities of both 5-FU and
Irinotecan restrict therapy to otherwise chemotherapeutic resistant tumors, and it was
feared that the cumulative effect of these combined toxicities would significantly impact
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possible synergy due to their similarities. This was not observed in practice 65. The FDA
approved Irinotecan therapy for advanced state colorectal cancer in patients which failed
to respond effectively to 5-FU treatment 19. A more recent study from the University of
Geneva attempted to maximize the efficiency of 5-FU and Irinotecan implementation by
testing various routes of administration. Their results dictate those combinations of low
dose chemotherapeutic agents yielded larger growth inhibition than solitary drugs 65.
However, it is important to note the distinction between the Geneva study and this
particular one. Clinical administration of 5-FU and Irinotecan typically occurs with
Irinotecan as the initial treatment followed by a bolus injection of 5-FU, and this was the
implementation within the Geneva study as well 65. Because the PMP cell lines tested in
our study are bereft of established dose response curves, it was decided to administer 5FU initially followed by Irinotecan. This sequence was chosen to help to establish a more
robust profile on the sensitivity of PMP derived cancers to Irinotecan. The PMP cell lines
were first treated with 100µM 5-FU for 6 hours and then Irinotecan for the remainder of
the 48 hours. 100µM was chosen for this combination therapy because previous
experimentation shows there was, at the highest, a 27.9% reduction of ATP values
compared to vehicle control. Higher concentrations of 5-FU show a marked inhibition of
cellular growth eclipsing a 50% reduction of ATP values as compared to control wells.
The intention of the multidrug treatment was to effectively weaken the PMP cancer cell
lines with the initial treatment of 5-FU. Once the cancer cells were primed by the 5-FU
the 96 well plate was treated with the same dosages of Irinotecan to once again test the
sensitivity of PMP cancer cell lines to Irinotecan. The mechanism between the two
cytotoxic agents have been explored previous studies, and is not discussed in this paper.
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The combination therapy data shows that each PMP cancer is affected to a greater
degree than simply Irinotecan as the sole agent (Fig 3.29). Because of this increased
sensitivity, LD50 could be calculated for every cell line in the trial. CO9-1 was the only
PMP cell line that had a LD50 higher than tested parameters (Fig 3.32), and CO5-1 (Fig
3.31) showed the most sensitivity to the combination therapy with a LD50 of 61.71 µM.
However, none of the PMP cell lines fell within acceptable Irinotecan plasma
concentrations with this specific administration of chemotherapies. These results could be
improved in the future by subjecting the cancers to a higher concentration of 5-FU prior
to Irinotecan therapy. As discussed earlier, 5-FU clinical doses correlate to peak plasma
concentrations of 426.19 µM. A modest increase to 300 µM 5-FU could theoretically
further improve PMP cell line responsiveness to Irinotecan therapy. In addition, the time
in which these cancers are bathed in each agent could yield improved results. The
Drewinko study observed that camptothecin progressively increases in cytotoxic activity
the longer it is exposed to tumors 13. Future studies should vary the time period of
treatment to determine whether or not PMP derived cancers respond similarly to
lymphoma cells with respect to treatment duration. In addition, a reversal of the
administration sequence mimicking clinical application should be explored.
4.6 Conclusions
Mitomycin C was the most effective chemotherapy agent in this study. Of the
tested chemotherapy agents only MMC was a non-cell cycle phase specific cytotoxic
agent. In addition, due to MMCs selective preference for solid tumors it is unsurprising
that this agent was so effective at both the 50,000 and 40,000 cell count experiments. The
other tested chemotherapies are sensitive to cellular proliferation, and the lack of growth
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observed at the 40,000 cell density could be responsible for the lack luster performances
of both Oxp and Irinotecan. 5-FU breaks the observed trend, with the majority of PMP
cell lines obtaining a calculated LD50 well within acceptable plasma ranges. 5-FU
attacks cells in S phase but is commonly utilized against solid tumors. The high cell
confluency within the 40,000 cell count growth experiment was an adequate analogue of
advanced cancer cell proliferation, but additional in vitro and in vivo testing is
recommended to validate 5-FU and the specific interaction with PMP cell lines. 5-FU is
shown to have no increased apoptosis inducing effects at hyperthermic temperatures,
unlike the three other tested chemotherapeutic agents 24, 8. It is then theorized that the
temperature of both Oxp and Irinotecan impacted their efficacy on the cancer cell lines.
Future experimentation could explore clinical durations of agent therapy at hyperthermic
temperatures, and this may further improve anti-cancer action on PMP derived cancers.
CO5-1 was observed to be the most sensitive cell line in this study. Calculated
LD50s were the lowest in the trial in 4 out of 6 experiments, and this cancer responded
favorably to multi-drug therapy. CO5-1 was removed from the colon of the patient, but
the location of the tumor seems to have no relevance to sensitivity in this study. Because
CO5-1 was removed from the distal colon, it seems counter intuitive that the cancer
responded so favorably to chemotherapy agents. In contrast, CO9-1, was one of the most
insensitive cancers in our study. The tumor was removed from the proximal colon of the
patient. Proximal colon mucinous adenocarcinomas typically have higher survival rates
than distal mucinous adenocarcinomas 34. ABX 023-1 was the second most sensitive
cancer, with the lowest calculated LD50 for both Oxp and Irinotecan therapy. In addition,
ABX 023-1 was recorded to have the second lowest calculated LD50 for both the
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Irinotecan therapy and the 40,000 MMC therapy. ABX 023-1 was classified as a PMCA
with signet ring cells. These two cancers are unique within this study. CO5-1 was
successfully transferred from human biopsies into immuno-deficient laboratory mice, and
ABX 023-1 was a PMCA cancer biopsy taken from a patient undergoing systemic
antibiotic therapy. Antibiotics are shown to minimize the aggressive nature of PMCA
class PMP cases 51. This could be evidence to explain why ABX 023-1 responded as well
as it did to chemotherapy. However, we could not draw any distinction between PMCA
and DPAM drug sensitivities. In addition, our results suggest that there are no clear
differences between the PMP cancers or the mucinous colorectal adenocarcinomas with
respect to growth or drug sensitivity. It is unclear whether or not the mouse host for CO51 affected any pathological sensitivity to these chemotherapies, but the results do imply
that this particular strain responds well to all chemotherapies tested. Whether or not this
is the result of the mouse host is unclear.
PMP is a devastating disease. Chemotherapy agents prove to be an effective
treatment strategy; however, this therapy is predicated on the stage of cancer
development. Early detection of PMP is difficult, but it is no less important than other
malignancies. CRS and HIPEC is shown to be an effective intervention for late stage
PMP. However, due to the advanced stage of this disease invasion into surrounding tissue
can occur. HIPEC is limited by the effective depth of perfusion into surrounding tissue.
This is an advantage compared to systemic chemotherapy, because the concentration of
agent can be safely increased in the operative theatre. This is also a disadvantage, because
based on the stage of development tissue invasion by malignant cells could outpace the
depth of drug perfusion or the sheer scope of cancer colonization might overwhelm the
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application. If the combination of CRS and HIPEC prove unsuccessful, traditional
systemic chemotherapy is also employed. Systemic chemotherapy does not allow the
physician to aggressively treat the cancer in the same parameters as HIPEC. In addition,
our results reinforce the unpredictable nature of agent interactions with cancer. Of the 4
unique chemotherapies in this study, only MMC and 5-FU resulted in a calculated LD50
within an acceptable clinical plasma concentration. Each of the tested agents are currently
used today as part of solitary or multidrug therapies with varying levels of success. It is in
bad faith to assume a predictable outcome of chemotherapeutic intervention based on
historical literature, and, in reality, a more personalized approach is necessary to
determine optimal treatment. The ability to detect and successfully treat PMP prior to
significant tissue invasion is paramount to patient health, however effective treatment
relies on exhaustive studies like ours. Our study is not intended as the final page for PMP
chemotherapy interactions, but rather another chapter to be utilized in the fight.
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